Form 4: United Therapeutics Exec Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, engaged in transactions on June 1, 2026.
• These transactions involved the exercise of 9,500 stock options at an exercise price of $146.03, resulting in the acquisition of 9,500 shares of common stock.
• Following the exercise, 1,365 shares were sold at a weighted average price of $545.0393, with subsequent sales of 2,213, 1,376, 1,546, 1,166, 1,070, 124, 240, and 400 shares at varying weighted average prices.
• These sales were conducted under a 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt beneficially owns 40,513 shares of common stock directly, with additional holdings indirectly through a spouse, and various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it details routine insider transactions under a pre-established plan rather than signaling new strategic developments or significant shifts in company performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and planned approach to stock sales, which can mitigate insider trading concerns.
• The Chairperson & CEO continues to hold a significant number of shares indirectly through trusts (324,443 shares) and directly (40,513 shares) after the reported transactions.

Negatives

• A substantial number of shares (totaling 9,500 shares from option exercises and subsequent sales) were disposed of by a key executive.
• The weighted average sale price of $545.0393 for the initial block of shares is significantly higher than the exercise price of $146.03, indicating a substantial profit was realized.

Risks

• The 10b5-1 plan is active until December 31, 2026, or until a large number of options are exercised, suggesting potential for further sales by the reporting person.
• The plan's continuation is tied to the exercise of options that expire in March 2027, which could lead to further sales activity as these options approach expiration.

Future Outlook

The 10b5-1 trading plan is active until December 31, 2026, or until 1,734,410 stock options are exercised, indicating potential for continued stock sales by the reporting person within this period.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO is a common strategy to diversify holdings or manage personal finances while adhering to insider trading regulations. The significant difference between the option exercise price and the sale price highlights the value appreciation of United Therapeutics' stock.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive may be perceived by some as a negative signal, although the use of a 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: The value of stock options exercised and sold reflects positively on the company's stock performance, which can be encouraging for employees holding equity.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2026, or until all 1,734,410 stock options are exercised.
• Further transactions may be reported on subsequent Form 4 filings if they occur under the existing plan.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, 10b5-1 Plan, Beneficial Ownership, United Therapeutics Corp, UTHR, Martine A. Rothblatt, Common Stock, Securities Transaction